|
" Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. "
Lacouture, Mario E; Anadkat, Milan J; Bensadoun, René-Jean; Bryce, Jane; Chan, Alexandre; Epstein, Joel B; Eaby-Sandy, Beth; Murphy, Barbara A; MASCC Skin Toxicity Study Group
| Document Type
|
:
|
AL
|
| Record Number
|
:
|
911766
|
| Doc. No
|
:
|
LA3g2647rb
|
| Title & Author
|
:
|
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. [Article]\ Lacouture, Mario E; Anadkat, Milan J; Bensadoun, René-Jean; Bryce, Jane; Chan, Alexandre; Epstein, Joel B; Eaby-Sandy, Beth; Murphy, Barbara A; MASCC Skin Toxicity Study Group
|
| Date
|
:
|
2011
|
| Title of Periodical
|
:
|
UC Irvine
|
| Abstract
|
:
|
BACKGROUND: Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities. METHODS: A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities. RESULTS: Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible. CONCLUSION: Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients' health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.
|
| |